Key facts
- Micron Biomedical’s last known valuation is $105.0M (Dec 2024).
- It has raised $32.0M across 3 recorded rounds; the latest was Early Stage VC ($15.0M) in Dec 2024.
- Notable investors include National Institutes of Health, Gates Foundation, J2 Ventures, Global Health Investment Corporation, BARDA — 12 tracked in total.
- Micron Biomedical has filed 3 Form Ds with the SEC since 2022, most recently Dec 2024 ($15.0M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Micron Biomedical
Funding rounds
3 roundsAbout Micron Biomedical
Operator of a biopharmaceutical company intended to develop microneedle patches for influenza and polio vaccines. The company's microneedle technology provides enhanced protective and therapeutic effects, patient compliance and simplified administration, enabling researchers to offer conventional vaccine delivery.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2009
- Employees
- 25
- Website
- micronbiomedical.com/
- Ownership
- Privately Held (backing)
Micron Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Micron Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Micron Biomedical in its N-PORT filings yet. We sweep new filings monthly.